OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.630
-0.140 (-7.91%)
At close: Apr 28, 2026, 4:00 PM EDT
1.680
+0.050 (3.07%)
After-hours: Apr 28, 2026, 8:00 PM EDT
OS Therapies Employees
As of December 31, 2025, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$5,750,769
Market Cap
68.52M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortress Biotech | 78 |
| Acrivon Therapeutics | 76 |
| ImmuCell | 73 |
| aTyr Pharma | 60 |
| PMV Pharmaceuticals | 54 |
| Pliant Therapeutics | 49 |
| Filana Therapeutics | 20 |
| MAIA Biotechnology | 13 |
OSTX News
- 1 day ago - OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET - Newsfile Corp
- 12 days ago - OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes - Newsfile Corp
- 15 days ago - OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor - Newsfile Corp
- 20 days ago - OS Therapies Appoints Craig Eagle, MD as Strategic Advisor - Newsfile Corp
- 26 days ago - OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors - Newsfile Corp
- 4 weeks ago - OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update - Newsfile Corp
- 4 weeks ago - OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma - Newsfile Corp
- 4 weeks ago - OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma - Newsfile Corp